Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
Recruiting · NCT03920618 · Interventional (participants receive a specific treatment) · Lead sponsor: Third Affiliated Hospital, Sun Yat-Sen University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
Who can take part
Age range
12 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Positive hepatitis b surface antigen or hepatitis b virus DNA \> 0.5 year;
- Age from 12 to 65 years old;
- Serum total bilirubin level \> 10 times upper limit of normal;
- Prothrombin time activity \< 40% or prothrombin time international ratio \> 1.5；
- Do not receive nucleotide/nucleoside analogues treatment in the past half year.
Exclusion criteria
- Other active liver diseases;
- Hepatocellular carcinoma or other malignancy;
- Pregnancy or lactation;
- Human immunodeficiency virus infection or congenital immune deficiency diseases;
- Severe diabetes, autoimmune diseases;
- Other important organ dysfunctions;
- Using glucocorticoid;
- Patients can not follow-up;
- Investigator considering inappropriate.
Where it is running
1 location listed.
- Third Affiliated Hospital of Sun Yat-sen University - Guangzhou, Guangdong, China